Premium
Whole‐body magnetic resonance imaging (WB‐MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: A pilot study
Author(s) -
Friedman Danielle Novetsky,
Lis Eric,
Sklar Charles A.,
Oeffinger Kevin C.,
Reppucci Marina,
Fleischut Megan Harlan,
Francis Jasmine H.,
Marr Brian,
Abramson David H,
Dunkel Ira J
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24835
Subject(s) - medicine , magnetic resonance imaging , retinoblastoma , radiology , genetics , gene , biology
Background Individuals with hereditary retinoblastoma (RB) are at very high risk of developing subsequent malignant neoplasms (SMNs) of which osteosarcoma (OS) is one of the most common. We hypothesized that annual surveillance using whole‐body magnetic resonance imaging (WB‐MRI) in asymptomatic survivors of hereditary RB would detect SMN of the bone and soft tissues at an early stage. Procedure Retrospective review of the results of a WB‐MRI screening program in hereditary RB survivors from February 2008 to August 2012. The primary outcome was to determine the sensitivity and specificity of WB‐MRI in detecting SMNs. Results Twenty‐five patients had at least one WB‐MRI performed (range: 1–5). First WB‐MRI was performed at a median age of 16 years (range: 8–25 years). WB‐MRI detected new osseous abnormalities suspicious for malignancy in five patients: two were diagnosed with localized high‐grade OS of the extremity and three were found to have benign osseous abnormalities after dedicated imaging (n = 5/5) and/or biopsy (n = 3/5). One patient was diagnosed with secondary OS 3 months after a normal screening WB‐MRI exam. Among a total of 41 WB‐MRI screening tests performed in survivors of hereditary RB, the sensitivity of detecting SMN was 66.7% and the specificity was 92.1%. Conclusions Preliminary results suggest that annual WB‐MRI surveillance detects SMN in survivors of hereditary RB, but with modest sensitivity. Further study is needed to assess the performance of annual surveillance WB‐MRIs and whether this modality decreases SMN‐related mortality in RB survivors. Pediatr Blood Cancer 2014; 61:1440–1444. © 2013 Wiley Periodicals, Inc.